This protocol provides detailed instructions for performing high-throughput, immunofluorescence-based ferritinophagy assessments in primary, skin-derived human fibroblasts.
Mutations in the autophagy gene WDR45/WIPI4 are the cause of beta-propeller-associated neurodegeneration (BPAN), a subtype of human diseases known as neurodegeneration with brain iron accumulation (NBIA) due to the presence of iron deposits in the brains of patients. Intracellular iron levels are tightly regulated by a number of cellular mechanisms, including the critical mechanism of ferritinophagy. This paper describes how ferritinophagy can be assessed in primary, skin-derived human fibroblasts. In this protocol, we use iron-modulating conditions for inducing or inhibiting ferritinophagy at the cellular level, such as the administration of bafilomycin A1 to inhibit lysosome function and ferric ammonium citrate (FAC) or deferasiox (DFX) treatments to overload or deplete iron, respectively. Such treated fibroblasts are then subjected to high-throughput imaging and CellProfiler-based quantitative localization analysis of endogenous ferritin and autophagosomal/lysosomal markers, here LAMP2. Based on the level of autophagosomal/lysosomal ferritin, conclusions can be drawn regarding the level of ferritinophagy. This protocol can be used to assess ferritinophagy in BPAN patient-derived primary fibroblasts or other types of mammalian cells.
The WIPI (WD-repeat interacting with phosphoinositides) proteins are evolutionarily conserved PI3P effectors with distinct roles in autophagy1. The four human WIPI proteins (WIPI1 through WIPI4) fold into seven-bladed β-propellers with two evolutionarily conserved regions in which homologous and invariant amino acids cluster on opposite sites of the propeller. One site is aligned with the phosphoinositide-binding region in propeller blade 5 and blade 6. The other site is aligned with the protein-protein interaction region where WIPIs associate with distinct members of the autophagy machinery or autophagy regulatory factors2.
WIPI4 functions in controlling energy-driven autophagy regulation and at the level of controlling the size of the growing nascent autophagosome3. A mutation in the WIPI4 gene, referred to as WDR45, is causative of beta-propeller-associated neurodegeneration (BPAN), a neurodegeneration with brain iron accumulation (NBIA) subtype in human patients that is characterized by a hypointense iron halo in the substantia nigra and globus pallidus4. The presence of abnormal iron deposits in BPAN patients provokes neuronal damage that translates into encephalopathy, global developmental delay, seizures, and ultimately, parkinsonism, dementia, and spasticity5.
Iron homeostasis is tightly regulated by multiple cellular mechanisms, with the concentration of cytosolic iron being controlled by the expression levels and functionality of iron carriers, iron transporters, and iron storage proteins6 . The concentration of cytosolic iron, in turn, determines whether degradation pathways such as ferritinophagy7 or the proteasomal clearance of oxidized ferritin8 are involved.
During ferritinophagy, ferritin is selectively recruited to autophagosomes by the cargo receptor NCOA4 and targeted for lysosomal degradation in response to low intracellular iron levels7. Given the role of WIPI4 in regulating the size of autophagosomal membranes3, it is reasonable to predict that the loss of this specific function may affect the selective sequestration of ferritin in autophagosomes and, thus, ferritinophagy. Studying this key step in iron metabolism may open doors to therapeutic options for BPAN patients; however, commonly used protocols to study ferritinophagy in human cells are only now being developed.
This paper describes a high-throughput, fluorescence-based method to assess ferritinophagy in human cells. The application of this assay to patient-derived BPAN cells can provide valuable insight into how ferritinophagy differs compared to healthy human cells and may serve as a benchmark for understanding the molecular mechanisms underlying this rare human disease.
1. Culturing and seeding primary cells
2. Treatments
3. Fixation and staining
4. Automated imaging using confocal laser-scanning microscopy
5. High-throughput image analysis
6. Data analysis
Human skin-derived primary fibroblasts (F-CO-60) from healthy donors (Figure 1A) were prepared for ferritinophagy assessments using baflomycin A1 treatment followed by immunostaining of endogenous ferritin and LAMP2, automated image analysis, and CellProfiler-based analysis (Figure 1B).
The colocalization of endogenous ferritin and LAMP2 increased after the lysosomal degradation of ferritin was blocked by the addition of bafilomycin A1, consistent with its ability to inhibit lysosomal V-ATPase enzymes and, thus, block ferritinophagy7 (Figure 2). In addition, the software-based cell recognition, as well as the ferritin and LAMP2 recognition, are shown as an example (Figure 2).
In this regard, it should be noted that the CellProfiler pipeline outlined here is extremely versatile and can be adapted to additional and/or alternative readouts, such as to assess the effects of certain BPAN mutations on cell growth, mitochondria, or other organelles in the context of functional single-cell marker systems.
Figure 1: Experimental overview. Graphical representation of (A) the process of ferritinophagy and (B) the experimental workflow to assess ferritinophagy in primary skin-derived human fibroblasts, as described in this protocol. Please click here to view a larger version of this figure.
Figure 2: Representative images. Primary skin-derived human fibroblasts in control medium (fed conditions) in the (A) absence or (B) presence of bafilomycin A1 were subjected to an indirect immunofluorescence analysis using anti-ferritin and anti-LAMP2 antibodies, while the cell nuclei were stained with DAPI. Exemplary fluorescence images acquired with confocal laser-scanning microscopy automation are presented (scale bars: 10 μm). Changes in ferritin and LAMP2 abundance and colocalization could be observed upon lysosomal inhibition upon bafilomycin A1 administration. The CellProfiler-based analysis is also displayed, showing the software-derived image overlays of cell recognition (purple), nuclei (blue), ferritin (green), LAMP2 (red), and co-localizing ferritin/LAMP2 (yellow) puncta. (C) Magnified image sections (scale bar = 10 µm). Please click here to view a larger version of this figure.
Table 1: The confocal laser-scanning microscopy settings used in this study. Please click here to download this Table.
Table 2: The numerical CellProfiler settings used in this study. Please click here to download this Table.
Supplemental File 1: The CellProfiler pipeline used in this study. Please click here to download this File.
Supplemental File 2: Display of the CellProfiler pipeline (see Supplemental File 1) with screenshots taken in consecutive order (see Table 2). Please click here to download this File.
This method, which uses automated fluorescence microscopy combined with open-access CellProfiler-based image analysis9 to assess the intracellular localization of key ferritinophagy factors, was designed to provide valuable information about the efficacy of lysosomal ferritin clearance via selective autophagy, referred to as ferritinophagy7. This protocol enables the handling of big sample sets with multiple cell lines and treatments simultaneously and the assessment of desired readouts, such as ferritin puncta numbers and ferritin puncta numbers colocalizing with LAMP2, which is a typical lysosomal marker for assessing the ferritinophagy flux. However, it should be emphasized here that accurate, automated image analysis depends on the image quality, which, in turn, depends on the antibody specificity and optimal imaging. Therefore, software-based image analysis should only be performed with high-quality images.
The modulation of iron levels in cells can provide valuable information about the mechanisms that are activated to regulate iron homeostasis in the context of disease. This paper describes a method to study BPAN diseases in patient-derived cells treated with iron-loading and iron-chelating agents. Deferasiox (DFX) is a known iron chelator used extensively in the field10. Upon application, it traps the free iron in the cytoplasm and triggers a cellular response to iron starvation. Since the aim of this study was to assess ferritinophagy, depriving the cells of iron was a straightforward way to promote ferritin degradation via autophagy as a compensation mechanism to replenish the cellular iron pool. Ferric ammonium citrate (FAC), on the contrary, is used to load cells with iron. Cells activate ferritin synthesis as a response to excessive and, thus, toxic cytosolic iron concentrations11. Ferric ammonium citrate, hence, promotes ferritin synthesis and the entrapment of iron within the ferritin heteropolymers, which can, in turn, activate ferritinophagy.
To study the ferritinophagic flux, in this protocol, we selectively stain the key players in the process-ferritin and the lysosomes (here marked by LAMP2)-and assess their colocalization. A high percentage of colocalizing puncta is indicative of effective lysosomal degradation of ferritin. To maximize the information retrieved from such experiments, additional dyes or marker antibodies can be used.
Of note, there are technical challenges inherent in this method. Primary fibroblasts derived from different human donors may proliferate and grow differently in vitro. Hence, for comparable results, different cells should be seeded at the same passage. Therefore, it is advisable to perform a test experiment before proceeding with this protocol to examine the doubling times of the cells or cell lines that are to be used.
This method is not restricted to the study of ferritinophagy; by simply changing the treatments and antibodies used, it can be repurposed to assess various other selective autophagy pathways; for example, mitophagy can be examined by using CCCP as a mitochondrial stress inducer and optineurin, LC3, and LAMP2 antibodies for the staining12.
Overall, the combination of automated image acquisition and CellProfiler analysis constitutes a powerful tool for the high-throughput functional assessment of single human fibroblasts. This is especially relevant for studying human diseases, for which the analysis and comparison of large cohorts of patient-derived cells and healthy donor-derived cells are of great interest.
The authors have nothing to disclose.
This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 259130777 – SFB 1177 (project E03). Figure 1 was created using BioRender.
Cell lines | |||
Primary skin-derived human fibroblasts | Skin biopsy, healthy human donor, Biobank University Clinic Tübingen, Ethical approvement 389/2019BO2 | F-CO-60, passage 9 | |
Cell culture treatments | Final concentration (compound) | ||
Control medium | DMEM 10%FCS | (DMSO only) | |
Control medium + bafilomycinA1 | DMEM 10%FCS | 100 nM bafilomycin A1 | |
Control medium + deferasiox (DFX) | DMEM 10%FCS | 30 µM DFX | |
Control medium + DFX + bafilomycinA1 | DMEM 10%FCS | 30 µM DFX, 100 nM bafilomycin A1 | |
Control medium + ferric ammonium citrate (FAC) | DMEM 10%FCS | 0.05 mg/mL FAC | |
Control medium + FAC + bafilomycinA1 | DMEM 10%FCS | 0.05 mg/mL FAC, 100 nM bafilomycin A1 | |
Material | |||
Albumin [BSA] Fraction V | AppliChem | A1391 | |
Alexa 488 goat a-rabbit | Life Technologies | A-11008 | |
Alexa 546 goat a-mouse | Life Technologies | A-11003 | |
Bafilomycin A1 | Sigma Aldrich | 196000 | |
BioLite Cell Culture treated 10cm dishes | Thermo Scientific | 130182 | |
DAPI | AppliChem | A4099 | |
Deferasiox (ICL-670) | Selleckchem | S1712 | |
DMEM Glutamax | Gibco | 31966 | |
DMSO | AppliChem | A3672 | |
DPBS no calcium nor magnesium | Gibco | 14190094 | |
Fetal bovine serum (FCS) | Gibco | 10437-028 | |
Ferric ammonium citrate (FAC) | Merck | F5879 | |
Anti-FERRITIN (Human Spleen) | Rockland | 200-401-090-0100 | |
LAMP2 (H4B4) | Santa Cruz | Sc-18822 | |
Paraformaldehyde (PFA) | Sigma-Aldrich | 441244 | |
PBS 10x Dulbecco’s | AppliChem | A0965 | |
PenStrep (1,00U/mL penicillin, 100 mg/mL streptomycin) | Life Technologies | 15140-122 | |
Trypsin-EDTA (0.05%) with phenol red | Gibco | 25300 | |
Tween20 | AppliChem | A4974 | |
96 well glass-bottom #0 plates | Cellvis | P96-0-N | |
Solution | |||
3.7% paraformaldehyde (PFA) | PFA dissolved in PBS, pH 7.5 | ||
Bafilomycin A1 100 mM stock | Bafilomycin A1 diluted in DMSO | ||
Ferric ammonium citrate (FAC) 100 mg/mL stock | FAC diluted in autoclaved double distilled water | ||
PBS/T | PBS, supplemented with 10% Tween20 | ||
PBS/T + BSA | PBS, supplemented with 10% Tween20, 1% BSA | ||
Software | |||
CellProfiler 4.2.4 | https://cellprofiler.org/ | ||
GraphPad Prism | Dotmatics | ||
Microsoft Excel Version 16.50 | Microsoft Office Plus 365 |